Open access
141
Views
34
CrossRef citations to date
0
Altmetric
Original Research
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial
Naimish R Patel1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden;2 Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Hospital, Boston, MA
, Danen M Cunoosamy1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Malin Fagerås1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Ziad Taib1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Sara Asimus1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Tove Hegelund-Myrbäck1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Sofia Lundin1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Katerina Pardali1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Nisha Kurian1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Eva Ersdal1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Cecilia Kristensson1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Katarina Korsback1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Robert Palmér1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden
, Mary N Brown3 Innovative Medicines and Early Development, AstraZeneca, Boston, MA, USA
, Steven Greenaway4 Quintiles Drug Research Unit at Guy’s Hospital, London
, Leonard Siew4 Quintiles Drug Research Unit at Guy’s Hospital, London
, Graham W Clarke4 Quintiles Drug Research Unit at Guy’s Hospital, London;5 Department of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, UK
, Stephen I Rennard6 Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska, Omaha, NE, USA;7 Clinical Discovery Unit, Innovative Medicines and Early Development, AstraZeneca, Cambridge, UK
, Barry J Make8 Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, University of Colorado, Denver, CO
, Robert A Wise9 Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
& Paul Jansson1 Innovative Medicines and Early Development, AstraZeneca, Gothenburg, SwedenCorrespondence[email protected]
show all
Pages 1009-1019
|
Published online: 27 Mar 2018
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.